Gene map of tumors could personalize cancer therapy

NCT ID NCT02215928

Recruiting now Knowledge-focused Sponsor: Stanford University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is looking at whether analyzing the DNA of a patient's tumor can help doctors pick more effective treatments. Researchers will profile tumors from 100 adults with advanced, incurable cancer to see if they can find genetic changes that match existing drugs or clinical trials. The goal is to learn if this personalized approach is practical and leads to better outcomes than standard care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: genomic profiling (tumor DNA analysis)
What this could lead to: If successful, this could show that analyzing a tumor's genes helps doctors choose more effective treatments for each patient, moving toward personalized cancer care.
What could go wrong: This is an early feasibility study with only 100 participants. It may not prove that gene-guided treatment improves outcomes, and many patients may not have actionable genetic changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer metastatic malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC

Contacts and locations

Locations

Stanford University
RECRUITING

Palo Alto, California, 94305, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.